Michael Snyder, MD
Ophthalmology · Cincinnati, OHNPI 1720075682
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $208,116 of the $215,734 with a category attached, or 96.5%. Haag-streit USA, Inc. accounts for 89.8% of it on its own, with 20 other manufacturers making up the rest. Reporting peaked in 2019 at $93,328 and has fallen 86.2% since, to $12,920 in 2025. Among ophthalmology clinicians in OH with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 75 payments — averaging $2876.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Haag-streit USA, Inc.$194K
- W. L. Gore & Associates, Inc.$18K
- Beaver-visitec International, Inc.$1K
- Johnson & Johnson Surgical Vision, Inc.$823
- Alcon$259
- Dompe US, Inc.$211
- plus $1K from 15 others
Across 1,012 payments — averaging $1102.36 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Alcon Research LLC$560K
- Johnson & Johnson Surgical Vision, Inc.$552K
- Bausch Health US, LLC$4K
What the payments were for
- Consulting fees$208,11696%
- Speaking & faculty fees$3,0001%
- Grants$7500%
- Food & beverage$2,6971%
- Education$1,1711%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Haag-streit USA, Inc.(2 entities) | 26 | $193,809 |
| W. L. Gore & Associates, Inc. | 14 | $18,025 |
| Beaver-visitec International, Inc. | 2 | $1,303 |
| Johnson & Johnson Surgical Vision, Inc. | 4 | $823 |
| Alcon | 7 | $259 |
| Dompe US, Inc. | 2 | $211 |
| Rxsight Inc | 2 | $194 |
| Harrow Eye, LLC | 3 | $176 |
| Bausch & Lomb Americas Inc. | 1 | $151 |
| Dutch Ophthalmic, USA | 1 | $150 |
| Mallinckrodt Hospital Products Inc. | 2 | $135 |
| Ivantis, Inc | 1 | $120 |
| Samsara Vision | 1 | $115 |
| Ocular Therapeutix, Inc. | 1 | $100 |
| Biotissue Holdings Inc. | 1 | $40 |
| AbbVie | 2 | $37 |
| Sun Pharmaceutical Industries Inc. | 1 | $24 |
| Johnson & Johnson | 1 | $19 |
| Novartis | 1 | $17 |
| AstraZeneca | 1 | $13 |
| Genentech USA, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Product in Development$17,938
- Device$1,050
- Tecnis IOL$750
- DEXTENZA$300
- Oxervate$211
- enVista MX60 IOL$151
- STELLARIS$151
- EVA, combined machine$150
- TISSUEBLUE$150
- Hydrus$120
- RXSIGHT CONTACT LENS$119
- RXSIGHT INJECTOR CARTRIDGE$119
- RXSIGHT INJECTOR HANDPIECE$119
- RXSIGHT LIGHT DELIVERY DEVICE (LDD)$119
- LIGHT ADJUSTABLE LENS (LAL)$119
- Implantable Miniature Telescope$115
- Clareon$103
How this compares
$215,734 in reported general payments places this provider in the 95th percentile of 640 ophthalmology providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ProlensaBromfenac Sodium | 69 | $23,566 |
| Prednisolone Acetate | 518 | $14,355 |
| Bromfenac Sodium | 65 | $11,751 |
| MoxifloxacinMoxifloxacin Hcl | 356 | $8,893 |
| IlevroNepafenac | 15 | $5,472 |
| Loteprednol Etabonate | 19 | $2,557 |
| Difluprednate | 20 | $2,014 |
| Ketorolac Tromethamine | 68 | $1,503 |
| ValacyclovirValacyclovir Hcl | 17 | $961 |
| Atropine Sulfate | 23 | $732 |
| Brimonidine Tartrate | 42 | $608 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 35 | $406 |
| Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha | 29 | $269 |
| Timolol Maleate | 37 | $177 |
| Latanoprost | 24 | $146 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| NovartisIlevro | $17 | $5,47215 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 640 ophthalmology providers in Ohio.
Other ophthalmology in Cincinnati
- Robert OsherCincinnati$720K
- Christopher RiemannCincinnati$463K
- Anup KhatanaCincinnati$347K
- Daniel MillerCincinnati$75K
- Robert SiskCincinnati$46K
- Michael NordlundCincinnati$40K
- Adam KaufmanCincinnati$19K
- Haroon ChaudhryCincinnati$18K
- Karen KlugoCincinnati$17K
- Clara ChanCincinnati$11K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.